US2022111158A1PendingUtilityA1

Delivery System For Ayahuasca-Like Substances

53
Assignee: ELLIS GREGORYPriority: Jul 29, 2020Filed: Dec 20, 2021Published: Apr 14, 2022
Est. expiryJul 29, 2040(~14 yrs left)· nominal 20-yr term from priority
Inventors:Gregory Ellis
A61M 2205/581A61M 2205/7545A61M 11/042A61K 9/0073A61K 31/4045A61K 47/10A61M 15/06A61M 2205/8206A61M 2205/6063C07B 2200/05A61M 2205/583A24F 40/00A61M 2209/06A61M 2205/6072A61M 2205/6018A61M 2205/582A61P 25/18
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is a delivery device and vaporizable formulations that provide users or patients with the ability to safely, reliably, and conveniently obtain a high-quality, therapeutic vapor comprising an ayahuasca-like substance. The delivery device includes a chamber coupled to a power unit capable of providing power to vaporize the formulations for consumption of the substance in a consistently desirable and safe manner. Further included are kits and methods of treating psychological disorders using the delivery device and vaporizable formulations provided herein.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method for delivering an ayahuasca-like substance, wherein the method comprises heating a vaporizable formulation comprising the ayahuasca-like substance to vaporize at least a portion of the vaporizable formulation. 
     
     
         22 . The method of  claim 21  wherein the vaporizable formulation is housed in a chamber comprising a top portion adapted for coupling to a mouthpiece wherein the top portion of the chamber comprises at least one aperture adapted to permit flow of air, liquid, solids, or vapor between the top portion of the chamber and the mouthpiece. 
     
     
         23 . The method of  claim 22  wherein the chamber comprises a mouthpiece coupled to the top portion of the chamber wherein the mouthpiece comprises a top aperture, a central open bore, a bottom portion comprising an aperture, and wherein the bottom portion of the mouthpiece is coupled to the top portion of the chamber. 
     
     
         24 . The method of  claim 23  wherein the chamber comprises at least one seal situated between the bottom portion of the mouthpiece comprising an aperture and the top portion of the chamber. 
     
     
         25 . The method of  claim 23  wherein the mouthpiece is releasably coupled to the top portion of the chamber. 
     
     
         26 . The method of  claim 23  wherein the mouthpiece is lockably coupled to the top portion of the chamber. 
     
     
         27 . The method of  claim 22  wherein the chamber comprises a bottom portion adapted for coupling to a power unit capable of providing power to vaporize the vaporizable formulation. 
     
     
         28 . The method of  claim 27  wherein the chamber is coupled to the power unit capable of providing power to vaporize the vaporizable formulation. 
     
     
         29 . The method of  claim 28  wherein the chamber is releasably coupled to the power unit. 
     
     
         30 . The method of  claim 28  wherein the chamber is lockably coupled to the power unit. 
     
     
         31 . The method of  claim 22  wherein the chamber comprises one or more of a 401, 510, 601, 610, 710, 808, 901, 4081, CE-4, CE-5, E9, or eGo connector. 
     
     
         32 . The method of  claim 31  wherein the chamber comprises an eGo connector. 
     
     
         33 . The method of  claim 31  wherein the chamber comprises a 510 connector. 
     
     
         34 . The method of  claim 22  wherein the chamber is refillable. 
     
     
         35 . The method of  claim 22  wherein the chamber is single-use. 
     
     
         36 . The method of  claim 23  wherein the chamber is transparent to permit visualization of levels of the vaporizable formulation. 
     
     
         37 . The method of  claim 21  wherein the ayahuasca-like substance or vaporizable formulation comprises one or more of dimethyltryptamine, a monoamine oxidase inhibitor, 5-methoxy-N, N-dimethyltryptamine, or 2-5-dimethoxy-4-bromophenethylamine. 
     
     
         38 . The method of  claim 37  wherein the ayahuasca-like substance comprises dimethyltryptamine. 
     
     
         39 . The method of  claim 37  wherein the ayahuasca-like substance comprises an isotopomer or isotopologue of one or more of dimethyltryptamine, a monoamine oxidase inhibitor, 5-methoxy-N,N-dimethyltryptamine, or 2-5-dimethoxy-4-bromophenethylamine. 
     
     
         40 . The method of  claim 39  wherein the isotopomer or isotopologue comprises deuterium. 
     
     
         41 . The method of  claim 39  wherein ayahuasca-like substance is dimethyltryptamine comprising deuterium. 
     
     
         42 . The method of  claim 21  wherein the vaporizable formulation comprises one or more of propylene glycol (PG), vegetable glycerin (VG), or polyethylene glycol (PEG). 
     
     
         43 - 89 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.